Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Pruritic, and Fibrotic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OSMR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OSMR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View OSMR Products |
| Gene Delivery | OSMR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for GPCR/Complex signaling validation without VLPs. |
View OSMR Products |
| Benchmark Ab | Anti-OSMR (Sequence of Vixarelimab) Recombinant positive control for binding and neutralization assays. |
View OSMR Products |
| Validator | OSMR siRNA Set For knockdown verification in primary cells or cell lines. |
View OSMR Products |
| Related Target A | OSM Ligand for OSMR/gp130 complex; critical driver of inflammatory and fibrotic pathways. |
View OSM Products |
| Related Target B | IL31RA Heterodimerizes with OSMR to form the functional IL-31 receptor complex, mediating pruritus. |
View IL31RA Products |
| Related Target C | IL6ST (gp130) Shared signal-transducing subunit that heterodimerizes with OSMR to mediate OSM signaling. |
View IL6ST Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dual-pathway cross-reactivity (OSM vs. IL-31 signaling) | Human/Cyno/Mouse OSMR orthologs available with high purity (>95%) for differential screening. |
| Conformational integrity of heterodimeric complexes | HEK293 Expressed (Native Glycosylation) proteins ensure correct folding and post-translational modifications. |
| Lack of Controls | Clinical Benchmark Antibodies (Vixarelimab biosimilar) included in the catalog. |
| False Positives in cellular assays | Validated siRNA sets included for specific target knockdown and validation. |
Live OSMR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OSMR therapeutics is intensifying, with major players shifting focus from traditional multi-cytokine inhibitors to highly specific OSMRβ monoclonal antibodies. OSMR (Oncostatin M Receptor) represents a unique nodal point in both neuro-immune signaling (via IL-31/IL-31RA/OSMRβ complex) and classical inflammatory pathways (via OSM/gp130/OSMRβ complex). As first-generation therapies like Vixarelimab demonstrate clinical efficacy in prurigo nodularis, the next wave of R&D is targeting chronic fibrotic diseases (such as systemic sclerosis and IBD) and tumor microenvironment modulation where OSMR-mediated gp130 signaling drives drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Kiniksa Pharmaceuticals, Sanofi | Prurigo Nodularis, Atopic Dermatitis, Chronic Pruritus | Dual blockade verification (OSM & IL-31 pathways) utilizing high-purity OSMR and IL31RA proteins. |
| Bispecific Antibody / Fusion | Academic Institutions, Biotech Startups | Inflammatory Bowel Disease (IBD), Fibrosis | Heterodimer validation requiring both OSMR and IL6ST (gp130) extracellular domains. |
| Small Molecule Inhibitors | Global Pharma | Oncology (Glioblastoma, CRC) | Downstream pathway screening requiring Lentivirus for stable OSMR/gp130 cell line generation. |